|
Diagnosis and management of urticaria in Indian settings: Skin allergy research society's guideline-2022
Kiran Godse1, Anant Patil2, Abhishek De3, Nidhi Sharma4, Muralidhar Rajagopalan5, Bela Shah6, Sushil Tahiliani7, Mukesh Girdhar8, Vijay Zawar9, Prabhakar Sangolli10, DS Krupa Shankar11, Sandipan Dhar12
1 From the Department of Dermatology, D Y Patil Hospital, Navi Mumbai, Maharashtra, India
2 Department of Pharmacology, D Y Patil Hospital, Navi Mumbai, Maharashtra, India
3 Department of Dermatology, Calcutta National Medical College, Kolkata, West Bengal, India
4 Department of Dermatology, The Medicity, Medanta Hospital, Gurugram, Haryana, India
5 Department of Dermatology, Apollo Hospital, Chennai, Tamil Nadu, India
6 Department of Dermatology, BJ Medical College, Ahmedabad, Gujarat, India
7 Department of Dermatology, PD Hinduja Hospital, Mumbai, Maharashtra, India
8 Department of Dermatology, Max Super Speciality Hospital, Patparganj, Delhi, India
9 Department of Dermatology, Skin Diseases Centre, Nashik, Maharashtra, India
10 Consultant Dermatologist, Skin Care Centre, Rajajinagar, Bengaluru, Karnataka, India
11 Department of Dermatology, Mallige Hospital, Bengaluru, Karnataka, India
12 Department of Dermatology, Institute of Child Health, Kolkata, West Bengal, India
Correspondence Address:
Abhishek De
Department of Dermatology, Calcutta National Medical College, Flat Number 3 A, Arcadia 1 Dream Park Sonarpur Station Road, Kolkata - 700 103, West Bengal
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijd.ijd_307_22
|
|
Urticaria is a common skin disorder. Chronic urticaria, i.e., the presence of symptoms for more than six weeks, is associated with a significant adverse impact on sleep, performance, quality of life, and financial status of the patients. Although several treatment options are available, the condition can be challenging to treat for many clinicians. Several updates have been published on the subject of urticaria and its management since the publication of an updated consensus statement in 2018 by Indian experts. The objective of this consensus statement is to summarize the updates and provide concise information, including classification, diagnosis, and management of urticaria. Understanding and elimination of the underlying eliciting trigger are essential in all possible cases. The goal of pharmacological treatment is to provide symptomatic relief. Second-generation nonsedating H1 antihistamine continue to be recommended as the first-line treatment, the dose of which can be increased up to four times in patients not responding satisfactorily, in the second step. The role of omalizumab, cyclosporine, H2 antihistamines, and other options is also discussed.
|
